Literature DB >> 33400290

IL-37-induced activation of glycogen synthase kinase 3β promotes IL-1R8/Sigirr phosphorylation, internalization, and degradation in lung epithelial cells.

Lian Li1, Jianxin Wei2, Tomeka L Suber2, Qinmao Ye1, Jiaxing Miao1, Shuang Li2, Sarah J Taleb1, Kevin C Tran1, Arya S Tamaskar1, Jing Zhao1,3, Yutong Zhao1,3.   

Abstract

Interleukin (IL)-37 diminishes a variety of inflammatory responses through ligation to its receptor IL-1R8/Sigirr. Sigirr is a Toll like receptor/IL-1R family member. We have shown that Sigirr is not stable in response to IL-37 treatment. IL-37-induced Sigirr degradation is mediated by the ubiquitin-proteasome system, and the process is reversed by a deubiquitinase, USP13. However, the molecular mechanisms by which USP13 regulates Sigirr stability have not been revealed. In this study, we investigate the roles of glycogen synthesis kinase 3β (GSK3β) in Sigirr phosphorylation and stability. IL-37 stimulation induced Sigirr phosphorylation and degradation, as well as activation of GSK3β. Inhibition of GSK3β attenuated IL-37-induced Sigirr phosphorylation, while exogenous expressed GSK3β promoted Sigirr phosphorylation at threonine (T)372 residue. Sigirr association with GSK3β was detected. Amino acid residues 51-101 in GSK3β were identified as the Sigirr binding domain. These data indicate that GSK3β mediates IL-37-induced threonine phosphorylation of Sigirr. Further, we investigated the role of GSK3β-mediated phosphorylation of Sigirr in Sigirr degradation. Inhibition of GSK3β attenuated IL-37-induced Sigirr degradation, while T372 mutant of Sigirr was resistant to IL-37-mediated degradation. Furthermore, inhibition of Sigirr phosphorylation prevented Sigirr internalization and association with USP13, suggesting GSK3β promotes Sigirr degradation through disrupting Sigirr association with USP13.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  GSK3β; IL-1R8/Sigirr; IL-37; phosphorylation; ubiquitination

Mesh:

Substances:

Year:  2021        PMID: 33400290      PMCID: PMC8809512          DOI: 10.1002/jcp.30253

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.513


  41 in total

1.  Ubiquitination-dependent regulation of signaling receptors in cancer.

Authors:  Wei-Chun Huangfu; Serge Y Fuchs
Journal:  Genes Cancer       Date:  2010-07

2.  The deubiquitinase ubiquitin-specific protease 20 is a positive modulator of myocardial β1-adrenergic receptor expression and signaling.

Authors:  Samuel Mon-Wei Yu; Pierre-Yves Jean-Charles; Dennis M Abraham; Suneet Kaur; Clarice Gareri; Lan Mao; Howard A Rockman; Sudha K Shenoy
Journal:  J Biol Chem       Date:  2018-12-11       Impact factor: 5.157

3.  SIGIRR inhibits toll-like receptor 4, 5, 9-mediated immune responses in human airway epithelial cells.

Authors:  Chun Zhang; Xueling Wu; Yunfeng Zhao; Zhaoxia Deng; Guisheng Qian
Journal:  Mol Biol Rep       Date:  2010-04-03       Impact factor: 2.316

4.  Ubiquitin Ligase, Fbw7, Targets CDX2 for Degradation via Two Phosphodegron Motifs in a GSK3β-Dependent Manner.

Authors:  Yogesh Kumar; Nidhi Shukla; Gatha Thacker; Isha Kapoor; Savita Lochab; Madan Lal Brahma Bhatt; Naibedya Chattopadhyay; Sabyasachi Sanyal; Arun Kumar Trivedi
Journal:  Mol Cancer Res       Date:  2016-07-28       Impact factor: 5.852

Review 5.  Suppression of inflammation and acquired immunity by IL-37.

Authors:  Giulio Cavalli; Charles A Dinarello
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

6.  Degradation of FBXO31 by APC/C is regulated by AKT- and ATM-mediated phosphorylation.

Authors:  Srinadh Choppara; Sunil K Malonia; Ganga Sankaran; Michael R Green; Manas Kumar Santra
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-17       Impact factor: 11.205

Review 7.  IL-1 Family Members in Cancer; Two Sides to Every Story.

Authors:  Kevin J Baker; Aileen Houston; Elizabeth Brint
Journal:  Front Immunol       Date:  2019-06-07       Impact factor: 7.561

8.  The deubiquitinase USP13 stabilizes the anti-inflammatory receptor IL-1R8/Sigirr to suppress lung inflammation.

Authors:  Lian Li; Jianxin Wei; Shuang Li; Anastasia M Jacko; Nathaniel M Weathington; Rama K Mallampalli; Jing Zhao; Yutong Zhao
Journal:  EBioMedicine       Date:  2019-06-14       Impact factor: 8.143

Review 9.  Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets.

Authors:  Lynn Bedford; James Lowe; Lawrence R Dick; R John Mayer; James E Brownell
Journal:  Nat Rev Drug Discov       Date:  2010-12-10       Impact factor: 84.694

10.  TIR8/SIGIRR is an Interleukin-1 Receptor/Toll Like Receptor Family Member with Regulatory Functions in Inflammation and Immunity.

Authors:  Federica Riva; Eduardo Bonavita; Elisa Barbati; Marta Muzio; Alberto Mantovani; Cecilia Garlanda
Journal:  Front Immunol       Date:  2012-10-29       Impact factor: 7.561

View more
  3 in total

Review 1.  Recent Advances in Progresses and Prospects of IL-37 in Central Nervous System Diseases.

Authors:  Xinrui Li; Bing Yan; Jin Du; Shanshan Xu; Lu Liu; Caifei Pan; Xianhui Kang; Shengmei Zhu
Journal:  Brain Sci       Date:  2022-05-31

Review 2.  Negative Regulation of the IL-1 System by IL-1R2 and IL-1R8: Relevance in Pathophysiology and Disease.

Authors:  Domenico Supino; Luna Minute; Andrea Mariancini; Federica Riva; Elena Magrini; Cecilia Garlanda
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

Review 3.  Current Understanding of IL-37 in Human Health and Disease.

Authors:  Zhangci Su; Xiaoan Tao
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.